The percentage of patients with severe heart failure (NYHA Class IV) was 29 percent and 43 percent for patients treated with OXYCONTIN and placebo, respectively. Mean (SD) steady state AUC0-24 was 33.4 ± 3.2 mcg.h/mL (range 30.4 to 36.0 mcg.h/mL). No treatment-emergent adverse reactions were observed at significantly higher rates with PREVACID three times daily plus oxycontin three times daily dual therapy than with PREVACID alone. SSRI antidepressants may cause serious or life-threatening lung problems in newborn babies whose mothers take the medication during pregnancy. Concomitant administration of CYP2D6 and/or CYP3A4 inhibitors (see CLINICAL PHARMACOLOGY, Pharmacokinetics), such as quinidine, fluoxetine, paroxetine and amitriptyline (CYP2D6 inhibitors), and oxycontin hydrocodone and erythromycin (CYP3A4 inhibitors), may reduce metabolic clearance of tramadol increasing the risk for serious adverse events including seizures and serotonin syndrome. US Patent No. Concomitant use of oxycontin and proton pump inhibitors is not recommended. Central & Peripheral Nervous System Disorders: Infrequent: neuropathy, apraxia, hyperaesthesia, dyskinesia, dysphonia, scotoma, ptosis, dystonia, visual field defect, encephalopathy, EEG abnormal. Pregnancy Exposure Registry: To provide information regarding the effects of in utero exposure to OXYCONTIN HYDROCODONE, physicians are advised to recommend that pregnant patients taking OXYCONTIN HYDROCODONE enroll in the North American Antiepileptic Drug (NAAED) Pregnancy Registry. For patients with creatinine clearance 10 mL/min (usually on hemodialysis) the recommended initial dose is 2.5 mg. The effects of OXYCONTIN in hospitalized depressed patients have not been adequately studied.